+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
MALE
ID07460843

Comparing Targeted and Perilesional Biopsy with Sextant-Systematic and Targeted Biopsy for Diagnosing Prostate Cancer in Men

Led by Peking University First Hospital · Updated on 2026-03-12

592

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two new prostate biopsy methods to improve the diagnosis of clinically significant prostate cancer csPCa. This randomized controlled trial compares targeted and perilesional biopsy TBPB with a combination of sextant-systematic biopsy and targeted biopsy TB6SB. The study aims to determine if TBPB improves diagnosis accuracy, whether TB6SB is not less effective than TBPB, and the value of TB6SB in detecting cancer in the prostate lobe opposite the main lesion. This is important because current biopsy methods may cause discomfort and miss some cancer areas due to tumor complexity and imaging limitations. Participants will be randomly assigned to receive either the TBPB or TB6SB biopsy procedure. Both procedures involve an MRI-targeted biopsy of suspicious prostate lesions. In TBPB, three targeted cores are taken within the MRI-identified lesion, followed by six cores taken in a ring around the lesion. In TB6SB, three targeted cores are taken within the lesion, followed by six systematic cores distributed bilaterally in specific prostate zones. Skilled urologists perform all biopsies using ultrasound guidance and prophylactic antibiotics. Each biopsy core is analyzed separately. During the study, participants will undergo the assigned biopsy procedure and have follow-up assessments one month later. Researchers will measure rates of clinically significant prostate cancer detection, overall prostate cancer detection, and pathological features from biopsy and surgical specimens when available. These outcomes will help compare the accuracy and diagnostic profiles of both biopsy methods. The trial runs from March 2026 to December 2026, with results expected to guide future prostate biopsy practices.

CONDITIONS

Brief Title

Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis

Research Team

Y

Yi Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here